Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02717611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv29
  2. Completion date: Sep 6, 2026 to Jun 6, 2026v28
  3. 5 versions Re-verified since Jul 30, 2024, no change to tracked fieldsv23-v27
  4. Completion date: Sep 1, 2026 to Sep 6, 2026v22
  5. Re-verified, no change to tracked fieldsv21
Show 19 earlier versionsHide 19 earlier versions
  1. Completion date: Dec 31, 2025 to Sep 1, 2026v20
  2. 6 versions Re-verified since Feb 17, 2022, no change to tracked fieldsv14-v19
  3. Results first posted: Feb 9, 2022 Secondary endpoints expanded, about 9 words · Primary endpoint revisedv13 Show 2 more changesShow less
    • Secondary endpoints expanded, about 9 words
    • Primary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  4. 2 versions Re-verified since May 24, 2021, no change to tracked fieldsv11-v12
  5. Primary completion date changed from estimate of Feb 2020 to Oct 16, 2020 Start date: Jan 2016 to Mar 8, 2016 · Primary endpoint revised · Study sites: 48 to 23 · 3 morev10 Show 6 more changesShow less
    • Start date: Jan 2016 to Mar 8, 2016
    • Primary endpoint revised
    • Study sites: 48 to 23
    • Completion date: Feb 2020 to Dec 31, 2025
    • Eligibility criteria expanded, about 165 words
    • Study description expanded, about 25 words

    See this version in full on ClinicalTrials.gov ↗

  6. Re-verified, no change to tracked fieldsv9
  7. Study sites: 49 to 48v8
  8. Re-verified, no change to tracked fieldsv7
  9. Trial status: Recruiting to Active, Not Recruiting Study sites revised (49)v6 Show 1 more changeShow less
    • Study sites revised (49)

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 36 to 49v5
  11. Study sites: 31 to 36v4
  12. Primary endpoint revised Enrollment target: 80 to 60 · Study sites: 18 to 31 · Eligibility criteria expanded, about 16 wordsv3 Show 3 more changesShow less
    • Enrollment target: 80 to 60
    • Study sites: 18 to 31
    • Eligibility criteria expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites: 6 to 18v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Trial Details
NCT Number NCT02717611
Lead Sponsor Acerta Pharma BV
Conditions Chronic Lymphocytic Leukemia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov